Johnson & Johnson (JNJ) to Withdraw the LINC Reflux Management System from Markets Outside the U.S.

Core Insights - Johnson & Johnson (NYSE: JNJ) is recognized as one of the 13 Best Diversified Stocks to Buy According to Hedge Funds due to its significant upside potential [1] Company Developments - On September 23, 2025, Johnson & Johnson announced plans to withdraw the LINC Reflux Management System from markets outside the U.S. by the end of March 2026 for commercial reasons, while the device will remain available in the U.S. [2] - Guggenheim raised its price target on Johnson & Johnson from $167 to $206, citing strong top-line growth in 2025 despite the loss of exclusivity for Stelara [3] - The company’s recently launched bladder cancer drugs, Inlexzo (TAR-200) and TAR-210, are projected to generate over $6 billion in sales at peak [3] Business Focus - Johnson & Johnson is engaged in research and development, manufacturing, and sales of a wide range of healthcare products globally, operating across pharmaceuticals, medical devices, and consumer health markets [4]